FDA Reviews GRAIL's Galleri Test; Medicare Coverage Set for 2029
Steady: 1 in the last 7 days
Updated tuesday
The latest in this situation
- New law enables Medicare coverage for Galleri starting in 2029.
- Favorable vote strengthens GRAIL's regulatory approval path, following results reported from Sunnyvale.
- FDA voted in favor of the safety and effectiveness of GRAIL's Galleri blood test.
- GRAIL receives FDA endorsement and secures investments from Samsung C&T and Samsung Electronics for Asian expansion.
How it started
AI-generated briefing. Brind wrote this from the reports listed below and has updated it as the story developed. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA is currently evaluating GRAIL's Galleri multi-cancer early detection test for breakthrough status. An FDA advisory panel voted on September 23, 2026, favoring the test's effectiveness and safety. Separately, a new federal law enables Medicare coverage for the test starting in 2029.
From 247wallst.com, yahoo.com
Why it matters
The regulatory approval from the FDA is critical for GRAIL's commercial viability and product adoption. The ability for Medicare to reimburse the $949 test starting in 2029 is a key factor for market expansion.
From 247wallst.com
Who's involved
- GRAILDeveloping the Galleri multi-cancer early detection test.
- FDAEvaluating the test for breakthrough status and reviewing its safety and effectiveness.
- MedicareThe US federal health insurance program that may cover the test starting in 2029.
- CongressPassed legislation enabling Medicare coverage for the test.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Quest Diagnostics may see increased volume from Galleri testQuest Diagnostics may see increased volume from Galleri testLikely
- Regulatory milestones could drive significant market valuation changes for GRAIL on NasdaqRegulatory milestones could drive significant market valuation changes for GRAIL on NasdaqLikely
- Medicare coverage for Galleri hinges on FDA vettingMedicare coverage for Galleri depends on rigorous FDA approval process.Possible
How it developed
Newest first. Tap a step to see who reported it.New law enables Medicare coverage for Galleri starting in 2029.1 source
- FDA voted in favor of the safety and effectiveness of GRAIL's Galleri blood test.Sub-event
- A key meeting was held to review the Galleri blood test developed by GRAIL.Sub-event
- GRAIL is pursuing commercialization and expansion of its Galleri test into Asian markets, including a collaboration in South Korea.Sub-event
Congress voted to allow Medicare reimbursement for Grail's Galleri test.1 source
FDA is evaluating GRAIL's Galleri multi-cancer early detection test for breakthrough status.1 source